[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Kevin Rakin Biography and Net Worth

Director of Oramed Pharmaceuticals

Mr. Rakin has been an Oramed Director since 2016. He is a Co-founder and Partner at HighCape Partners, a growth equity life sciences fund. Previously, Mr. Rakin was the President of Regenerative Medicine at Shire plc, and served as the Chairman and Chief Executive Officer of Advanced BioHealing, Inc. from 2007 until its acquisition by Shire for $750 million in June 2011. Mr. Rakin currently serves on the board of Histogenics Corporation.

How do I contact Kevin Rakin?: The corporate mailing address for Mr. Rakin and other Oramed Pharmaceuticals executives is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. Oramed Pharmaceuticals can also be reached via phone at (844) 967-2633 and via email at [email protected]. Learn More on Kevin Rakin's contact information.
Has Kevin Rakin been buying or selling shares of Oramed Pharmaceuticals?: Kevin Rakin has not been actively trading shares of Oramed Pharmaceuticals within the last three months. Most recently, Kevin Rakin sold 10,000 shares of the business's stock in a transaction on Monday, March 21st. The shares were sold at an average price of $9.41, for a transaction totalling $94,100.00. Learn More on Kevin Rakin's trading history.
Who are Oramed Pharmaceuticals' active insiders?: Oramed Pharmaceuticals' insider roster includes Nadav Kidron (CEO), and Kevin Rakin (Director). Learn More on Oramed Pharmaceuticals' active insiders.

Kevin Rakin Insider Trading History at Oramed Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/21/2022	Sell	10,000	$9.41	$94,100.00
9/16/2021	Sell	21,100	$20.99	$442,889.00

Kevin Rakin Buying and Selling Activity at Oramed Pharmaceuticals

Oramed Pharmaceuticals Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Today's Range

Now: $2.34

$2.30

$2.39

50 Day Range

MA: $2.36

$2.17

$2.51

2 Week Range

Now: $2.34

$2.00

$3.67

Volume

106,953 shs

Average Volume

113,440 shs

Market Capitalization

$94.33 million

P/E Ratio

4.59

Dividend Yield

N/A

Beta

1.77